Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOS-1584 in previously treated advanced NSCLC
NCT00651508Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2008
- Primary completion
- Oct 2008
- Countries
- 1
- Sponsor
- Bristol Myers Squibb
- Modality
- RNA-Targeting Small Molecules
- Drugs
- KOS-1584
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of KOS-1584 in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate at 1 year. Started Apr 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Single Arm 25mg/m2
KOS-1584 25mg/m2 IV
03
Who it enrols
Patients with Stage IIIB or IV NSCLC who have received only one prior chemotherapy regimen and have good performance status.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression Free Survival
Time to Progression
Time to Treatment Failure
Duration of Response
Overall Survival
Safety
Beyond the preview
Go deeper on NCT00651508.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651508.